A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

September 11, 2026 updated by: GlaxoSmithKline

A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

471

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Buenos Aires, Argentina, C1425BEN
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Buenos Aires, Argentina, C1425AZE
        • GSK Investigational Site
      • La Plata, Argentina, 1900
        • GSK Investigational Site
      • Mendoza, Argentina, M5500CCG
        • GSK Investigational Site
    • New South Wales
      • Botany, New South Wales, Australia, 2019
        • GSK Investigational Site
      • Coffs Harbour, New South Wales, Australia, 2450
        • GSK Investigational Site
      • Kanwal, New South Wales, Australia, 2259
        • GSK Investigational Site
    • Western Australia
      • Spearwood, Western Australia, Australia, 6163
        • GSK Investigational Site
    • Ontario
      • Ajax, Ontario, Canada, L1S 2J5
        • GSK Investigational Site
      • Brampton, Ontario, Canada, L6T 0G1
        • GSK Investigational Site
      • Ottawa, Ontario, Canada, K1H 1E4
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M9V 4B4
        • GSK Investigational Site
      • Windsor, Ontario, Canada, N8X 2G1
        • GSK Investigational Site
    • Quebec
      • Québec, Quebec, Canada, G1V 4W2
        • GSK Investigational Site
      • Québec, Quebec, Canada, G1W 4R4
        • GSK Investigational Site
      • Amiens, France, 80054
        • GSK Investigational Site
      • Argenteuil, France, 95100
        • GSK Investigational Site
      • Créteil, France, 94010
        • GSK Investigational Site
      • Poitiers, France, 86021
        • GSK Investigational Site
      • Pontoise, France, 95303
        • GSK Investigational Site
      • Strasbourg, France, 67091
        • GSK Investigational Site
      • Athens, Greece, 15669
        • GSK Investigational Site
      • Larissa, Greece, 41110
        • GSK Investigational Site
      • Thessaloniki, Greece, 57010
        • GSK Investigational Site
      • Cagliari, Italy, 09042
        • GSK Investigational Site
      • Florence, Italy, 50134
        • GSK Investigational Site
      • Foggia, Italy, 71100
        • GSK Investigational Site
      • Milan, Italy, 20162
        • GSK Investigational Site
      • Naples, Italy, 80131
        • GSK Investigational Site
      • Padova, Italy, 35128
        • GSK Investigational Site
      • Torino, Italy, 10128
        • GSK Investigational Site
      • Tradate VA, Italy, 21100
        • GSK Investigational Site
      • Verona, Italy, 37134
        • GSK Investigational Site
    • RM
      • Roma, RM, Italy, 00161
        • GSK Investigational Site
      • Panama City, Panama
        • GSK Investigational Site
      • Panama City, Panama, 7099
        • GSK Investigational Site
      • Panama City, Panama, 7002
        • GSK Investigational Site
      • Iloilo City, Philippines, 5000
        • GSK Investigational Site
      • Bialystok, Poland, 15-010
        • GSK Investigational Site
      • Bielsko-Biala, Poland, 43-300
        • GSK Investigational Site
      • Chorzów, Poland, 41-500
        • GSK Investigational Site
      • Elblag, Poland, 82-300
        • GSK Investigational Site
      • Katowice, Poland, 40-600
        • GSK Investigational Site
      • Ostrowiec Świętokrzyski, Poland, 27-400
        • GSK Investigational Site
      • Płock, Poland, 09-407
        • GSK Investigational Site
      • Tarnów, Poland, 33-100
        • GSK Investigational Site
      • Barcelona, Spain, 08017
        • GSK Investigational Site
      • Barcelona, Spain, 08540
        • GSK Investigational Site
      • Benalmádena, Spain, 29631
        • GSK Investigational Site
      • Madrid, Spain, 28041
        • GSK Investigational Site
      • Madrid, Spain, 28040
        • GSK Investigational Site
      • Madrid, Spain, 28031
        • GSK Investigational Site
      • Marbella, Spain, 29603
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spain, 28223
        • GSK Investigational Site
      • Pathum Thani, Thailand, 12120
        • GSK Investigational Site
      • Bebington, United Kingdom, CH63 9JP
        • GSK Investigational Site
      • Cambridgeshire, United Kingdom, CB7 5JD
        • GSK Investigational Site
      • Corby, United Kingdom, NN17 2UR
        • GSK Investigational Site
      • Greater Manchester, United Kingdom, OL6 6HD
        • GSK Investigational Site
      • Guisborough, United Kingdom, TS14 7DJ
        • GSK Investigational Site
      • Hounslow, United Kingdom, TW3 3EL
        • GSK Investigational Site
      • Rhyl, United Kingdom, LL18 4HZ
        • GSK Investigational Site
      • Uttoxeter, United Kingdom, ST14 5JX
        • GSK Investigational Site
    • California
      • North Hollywood, California, United States, 91606-3287
        • GSK Investigational Site
      • San Mateo, California, United States, 94403
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, United States, 33180
        • GSK Investigational Site
      • Clearwater, Florida, United States, 33756
        • GSK Investigational Site
      • DeLand, Florida, United States, 32720
        • GSK Investigational Site
      • Miami, Florida, United States, 33173
        • GSK Investigational Site
      • Miami, Florida, United States, 33144
        • GSK Investigational Site
      • Miami, Florida, United States, 33155
        • GSK Investigational Site
      • Naples, Florida, United States, 34102
        • GSK Investigational Site
      • Plantation, Florida, United States, 33317
        • GSK Investigational Site
      • Winter Park, Florida, United States, 32789-3385
        • GSK Investigational Site
    • Georgia
      • Rincon, Georgia, United States, 31326-5131
        • GSK Investigational Site
      • Stonecrest, Georgia, United States, 30038
        • GSK Investigational Site
    • Kentucky
      • Louisville, Kentucky, United States, 40217
        • GSK Investigational Site
      • Owensboro, Kentucky, United States, 42301
        • GSK Investigational Site
    • Massachusetts
      • Fall River, Massachusetts, United States, 02723-1511
        • GSK Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, United States, 55402-2508
        • GSK Investigational Site
      • Minneota, Minnesota, United States, 56001
        • GSK Investigational Site
    • Mississippi
      • Olive Branch, Mississippi, United States, 38654
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, United States, 65203
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, United States, 89052-5015
        • GSK Investigational Site
    • New Jersey
      • Jersey City, New Jersey, United States, 07306
        • GSK Investigational Site
      • Riverdale, New Jersey, United States, 07457
        • GSK Investigational Site
    • New York
      • Brooklyn, New York, United States, 11220
        • GSK Investigational Site
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • GSK Investigational Site
      • Winston-Salem, North Carolina, United States, 27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, United States, 45231
        • GSK Investigational Site
      • Dublin, Ohio, United States, 43016
        • GSK Investigational Site
    • Oregon
      • Medford, Oregon, United States, 97504
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, United States, 15241
        • GSK Investigational Site
      • Pottstown, Pennsylvania, United States, 19464-3241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill, South Carolina, United States, 29732
        • GSK Investigational Site
      • Spartanburg, South Carolina, United States, 29303
        • GSK Investigational Site
      • Spartanburg, South Carolina, United States, 29303-4225
        • GSK Investigational Site
      • Union, South Carolina, United States, 29379-7409
        • GSK Investigational Site
    • Texas
      • Sugar Land, Texas, United States, 77479
        • GSK Investigational Site
      • Tomball, Texas, United States, 77375-3332
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.

  2. Asthma for ≥ 6 months, defined as:

    • Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]

    • Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:

      • Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
      • Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
      • Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
      • Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
  3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)

  4. Asthma Control Status

    • Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening

    • Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:

      • Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
      • An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
  5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.

  6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):

    • With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.

    • Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.

      • SABA should be withheld for ≥6 hours
      • Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
  7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:

    • Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.

      • SABA should be withheld for ≥6 hours
      • LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.

Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.

Exclusion Criteria:

  1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
  2. Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
  3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
  4. Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
  5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Salbutamol HFA-152a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 μg (ex-valve) at 30-second intervals per actuation

Active Comparator: Salbutamol HFA-134a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 microgram (μg) (ex-valve) at 30-second intervals per actuation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Adverse Events (AEs) During Run-in Period
Time Frame: From Week -1 up to randomization (Day 1) during Run-in period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Adverse Events (AEs) During Treatment Period
Time Frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
Time Frame: From Week -1 up to randomization (Day 1) during Run-in period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
Time Frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Absolute Values of Minimum Serum Potassium
Time Frame: Up to Week 13 (Follow up)

Blood samples were collected to analyze minimum serum potassium.

Up to Week 13 (Follow up)
Absolute Values of Serum Potassium at Each Assessed Visit
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Erythrocytes
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Erythrocytes
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCV
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCH
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hematocrit
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hematocrit
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Specific Gravity
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Specific Gravity
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
Time Frame: Up to Week 13 (Follow up)

Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.

Up to Week 13 (Follow up)
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Vital Signs: Pulse Rate
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Pulse Rate
Time Frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
Time Frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline for 12 Lead ECGs in QTcF
Time Frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Heart Rate
Time Frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Heart Rate
Time Frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
Time Frame: Baseline (Day 1, pre-dose) and Week 12

The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: Baseline (Day 1, pre-dose) and Week 12

Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: GSK Clinical Trials, GlaxoSmithKline

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2024

Primary Completion (Actual)

September 2, 2025

Study Completion (Actual)

September 2, 2025

Study Registration Dates

First Submitted

February 8, 2024

First Submitted That Met QC Criteria

February 8, 2024

First Posted (Actual)

February 15, 2024

Study Record Updates

Last Update Posted (Actual)

October 6, 2026

Last Update Submitted That Met QC Criteria

September 11, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 220735
  • 2023-509001-76-00 (Other Identifier: EU CT Number)
  • 2023 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD Sharing Time Frame

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD Sharing Access Criteria

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe